Computerized and on-line neuropsychological testing for late-life cognition and neurocognitive disorders: are we there yet?

被引:41
|
作者
Gates, Nicola J. [1 ]
Kochan, Nicole A. [1 ,2 ]
机构
[1] Univ New S Wales, Ctr Hlth Brain Ageing CHeBA UNSW Med, Sydney, NSW, Australia
[2] Prince Wales Hosp, Inst Neuropsychiat, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
cognitive assessment; computerized tests; dementia; mild cognitive impairment; neuropsychological test; ALZHEIMERS-DISEASE; SCREENING-TEST; IPAD VERSION; IMPAIRMENT; BATTERY; VALIDATION; DEMENTIA; TOOLS; RELIABILITY; PERFORMANCE;
D O I
10.1097/YCO.0000000000000141
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of review Cost-effective, valid, efficient and accessible tests for the detection of late-life neurocognitive disorders are crucial, as early identification facilitates appropriate early intervention. Proponents of computerized neuropsychological assessment devices (CNADs) assert that technology-based assessments improve upon traditional neuropsychological tests. However, there remain fundamental questions of validity, reliability, normative data and administration, raising the question of whether CNADs are appropriate alternatives. Recent findings Since publication of the 2012 American Academy of Clinical Neuropsychology and National Academy of Neuropsychology joint position paper outlining appropriate standards for CNAD development, the field has not significantly advanced, with the majority of recommendations inadequately addressed. Summary Whilst there is a pressing need for innovative and readily applicable cognitive tests, these requirements do not outweigh the necessity for valid measures. Overall, the psychometric quality, standardization, normative data and administration advice of CNADs for neurocognitive disorders are lacking. Therefore, the risk of diagnostic errors is potentially high and poor clinical decisions could potentially arise, having significant impact upon individuals in terms of their well being and access to treatment. We recommend clinicians and researchers make informed decisions about CNAD suitability for their clients and their individual requirements based upon published psychometric and other test information.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 9 条
  • [1] Cognition in late-life bipolar disorders
    Strejilevich, S. A.
    BIPOLAR DISORDERS, 2013, 15 : 18 - 18
  • [2] Current Diagnostic Challenges in Late-Life Depression and Neurocognitive Disorders
    Adriani, Barbara
    Arena, Jan Francesco
    Fioretti, Alessandro
    Mancino, Serena
    Sarno, Francesca
    Ferracuti, Stefano
    Del Casale, Antonio
    PSYCHIATRY INTERNATIONAL, 2024, 5 (04): : 904 - 916
  • [3] Computerized Neuropsychological Testing to Rapidly Evaluate Cognition in Pediatric Patients With Neurologic Disorders
    Brooks, Brian L.
    Sherman, Elisabeth M. S.
    JOURNAL OF CHILD NEUROLOGY, 2012, 27 (08) : 982 - 991
  • [4] Correlation between cognition and symptomatic severity in patients with late-life somatoform disorders
    Inamura, Keisuke
    Tsuno, Norifumi
    Shinagawa, Shunichiro
    Nagata, Tomoyuki
    Tagai, Kenji
    Nakayama, Kazuhiko
    AGING & MENTAL HEALTH, 2015, 19 (02) : 169 - 174
  • [6] Treatment of Late-Life Mental Disorders in Primary Care: We Can Do a Better Job
    Moak, Gary S.
    JOURNAL OF AGING & SOCIAL POLICY, 2011, 23 (03) : 274 - 285
  • [7] Effect of computerized cognitive training on mood, cognition, and serum brain-derived neurotrophic factor level in late-life depression - a pilot randomized controlled trial
    Ma, Suk Ling
    Tang, Katsie Tung
    Lau, Niki Cheuk Ting
    Chiu, Clement Lek Hin
    Lin, Cuichan
    Lam, Linda Chiu Wa
    Lee, Allen Ting Chun
    FRONTIERS IN PSYCHIATRY, 2024, 14
  • [8] Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?
    Laliberte, Vincent
    Yu, Ching
    Rej, Soham
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2015, 40 (04): : E29 - E30
  • [9] Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
    Seripa, Davide
    Lozupone, Madia
    Stella, Eleonora
    Paroni, Giulia
    Bisceglia, Paola
    La Montagna, Maddalena
    D'onofrio, Grazia
    Gravina, Carolina
    Urbano, Maria
    Priore, Maria Giovanna
    Lamanna, Angela
    Daniele, Antonio
    Bellomo, Antonello
    Logroscino, Giancarlo
    Greco, Antonio
    Panza, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1373 - 1385